INGELHEIM, Germany - Tuesday, September 2nd 2014 [ME NewsWire]
RE-LY® sub-analysis shows that Pradaxa® treatment favourably affects kidney function1 deterioration over time compared to warfarin
Data provide additional support for long-term use of Pradaxa® in stroke prevention in non-valvular atrial fibrillation (NVAF)1
(BUSINESS WIRE)-- Non-US/Non-UK/Non-Canadian Media
New data presented today indicate that kidney function decline is less pronounced in patients with an irregular heartbeat (non-valvular atrial fibrillation, NVAF) who are treated with Pradaxa®(dabigatran etexilate) compared to warfarin.1 A natural decline in kidney function is expected as part of the ageing process or as a result of other underlying diseases.2 New data support that long-term Pradaxa® treatment compares favourably to warfarin in terms of kidney function decline over time.1 The new RE-LY® study sub-analysis findings were presented today at a Clinical Trial Update Hot Line session during the ESC Congress 2014 organised by the European Society of Cardiology in Barcelona.1
“These data support dabigatran as a good long-term treatment option for non-valvular atrial fibrillation patients,” said Professor Michael Böhm, Director of the Department of Internal Medicine and Cardiology at the University Hospital of Saarland, Homburg/Saar, Germany. “These RE-LY® study findings may have particular relevance for NVAF patients who have co-existing medical conditions which negatively impact their kidney function, such as diabetes, and for patients with poorly controlled vitamin K antagonist therapy. Dabigatran may provide additional benefit to these patients in the long term.”
The data included in the ESC Congress 2014 Hot Line session were derived from a post hoc exploratory analysis of the RE-LY® study that included over 18,000 patients and compared kidney function change in patients treated with either warfarin or Pradaxa® (110mg or 150mg twice daily).1
Results indicate that kidney function deteriorated more in patients on warfarin compared to those on either dose of Pradaxa®.1 Results were significantly different to warfarin for both doses of Pradaxa®at 30 months, with similar patterns seen in different Pradaxa® subgroups.1 Patients who were poorly controlled on warfarin and spent more time above the recommended International Normalized Ratio target range (INR 2-3) experienced a markedly sharper decline in kidney function compared to patients taking Pradaxa®.1 Patients with diabetes, who are at generally higher risk of kidney problems were particularly susceptible to the effects of warfarin, and experienced higher rates of kidney decline than non-diabetic NVAF patients.1 The same was true for patients previously treated with warfarin.1 Also in these patients, Pradaxa® treatment compared favourably to warfarin.1
While the exact mechanism behind this difference has yet to be identified, there is a well-defined pathophysiological background. Vitamin K is known to protect against the build-up of calcium deposits in blood vessels, known as vascular calcification.3 Oral anticoagulation with vitamin K-antagonists such as warfarin, which block vitamin K in the body, have been associated with an increased rate of vascular calcification and vascular damage.3 Pradaxa® is an oral direct thrombin inhibitor which does not interfere with vitamin K, but works in a different way to reduce blood clotting in order to protect patients with non-valvular atrial fibrillation against stroke.4,5,6
~ENDS~
Please click on the link below for ‘Notes to Editors‘ and ‘References‘:
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/02_september_2014_dabigatranetexilate.html
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Friederike Middeke
55216 Ingelheim/Germany
Phone: +49 6132 – 77 141 575
Email: press@boehringer-ingelheim.com
Permalink: http://me-newswire.net/news/11967/en
| 
